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Abstract
Background: To quantify mitral regurgitation (MR) with CMR, the regurgitant volume can be calculated as the difference
between the left ventricular (LV) stroke volume (SV) measured with the Simpson’s method and the reference SV, i.e. the
right ventricular SV (RVSV) in patients without tricuspid regurgitation. However, for patients with prominent mitral valve
prolapse (MVP), the Simpson’s method may underestimate the LV end-systolic volume (LVESV) as it only considers the
volume located between the apex and the mitral annulus, and neglects the ventricular volume that is displaced into the
left atrium but contained within the prolapsed mitral leaflets at end systole. This may lead to an underestimation of
LVESV, and resulting an over-estimation of LVSV, and an over-estimation of mitral regurgitation. The aim of the present
study was to assess the impact of prominent MVP on MR quantification by CMR.
Methods: In patients with MVP (and no more than trace tricuspid regurgitation) MR was quantified by calculating the
regurgitant volume as the difference between LVSV and RVSV. LVSVuncorr was calculated conventionally as LV end-diastolic
(LVEDV) minus LVESV. A corrected LVESVcorr was calculated as the LVESV plus the prolapsed volume, i.e. the volume
between the mitral annulus and the prolapsing mitral leaflets. The 2 methods were compared with respect to the MR
grading. MR grades were defined as absent or trace, mild (5–29% regurgitant fraction (RF)), moderate (30–49% RF), or
severe (≥50% RF).
Results: In 35 patients (44.0 ± 23.0y, 14 males, 20 patients with MR) the prolapsed volume was 16.5 ± 8.7 ml. The 2
methods were concordant in only 12 (34%) patients, as the uncorrected method indicated a 1-grade higher MR severity
in 23 (66%) patients. For the uncorrected/corrected method, the distribution of the MR grades as absent-trace (0 vs 11,
respectively), mild (20 vs 18, respectively), moderate (11 vs 5, respectively), and severe (4 vs 1, respectively) was
significantly different (p < 0.001). In the subgroup without MR, LVSVcorr was not significantly different from RVSV
(difference: 2.5 ± 4.7 ml, p= 0.11 vs 0) while a systematic overestimation was observed with LVSVuncorr (difference: 16.9 ± 9.
1 ml, p = 0.0007 vs 0). Also, RVSV was highly correlated with aortic forward flow (n = 24, R2 = 0.97, p< 0.001).
Conclusion: For patients with severe bileaflet prolapse, the correction of the LVSV for the prolapse volume is suggested
as it modified the assessment of MR severity by one grade in a large portion of patients.
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Background
Mitral regurgitation (MR) is one of the most common
valve diseases with an estimated prevalence of 1.7% in
the general population, increasing to 9.3% after age 75.
Moderate to severe MR represents an important public
health issue as it is associated with poor clinical outcome
[1]. Degenerative mitral valve prolapse (MVP) is consid-
ered as one of the most common causes of MR in the
general population [2] and it accounts for 60 to 70% of
cases in surgical series [3]. MVP is defined as a systolic
excursion of the mitral leaflets >2 mm behind the mitral
annular plane in long axis view, i.e. a displacement of
>2 mm into the left atrium (LA) [4].
In general, for the quantification of MR severity echo-
cardiography is the method of choice, although some
limitations exist. For example, the most frequently used
technique, the proximal isovelocity surface area (PISA)
method [5], may be technically challenging in mitral
valve prolapse patients as the effective regurgitant orifice
may vary during systole [6, 7], potentially leading to
inaccurate grading of severity. A recent study suggested
that cardiovascular magnetic resonance (CMR) might be
superior to echocardiography in identifying MR patients,
who will benefit most from mitral surgery in terms of
post-operative left ventricular (LV) remodelling [8]. By
accurately measuring volumes and flows [9], CMR is an
attractive method to quantify mitral regurgitant volume
(RegVol) and regurgitant fraction (RF), two parameters
that may be able to identify patients suitable for early
surgery [10]. Several techniques have been validated for
RegVol calculation, which are based on the difference
between the LV stroke volume (SV) measured with the
Simpson’s method and a reference SV either measured
as the aortic forward flow (Aoforward) by phase-contrast
cine CMR at the level of the ascending aorta or as the
right ventricular (RV) SV by the Simpson’s method
(assuming the absence of significant associated aortic,
pulmonary or tricuspid regurgitation) [11–18].
With the method of disks, the end-diastolic and end-
systolic volumes are measured by tracing the endocardial
border of consecutive short-axis cine slices covering the
LV from the apex to the mitral annulus. For patients
with prominent MVP, this strategy may be inaccurate in
systole as the part of the LV volume contained within
the prolapsing mitral leaflets (ie behind the mitral
annulus) at end-systole is simply neglected and excluded
from the total LV end-systolic volume (and erroneously
considered as being part of the left atrial volume). Thus,
the currently accepted approaches [11–18] do not take
into account the anatomical features of MVP. We
hypothesized that this LVESV underestimation leads to
an overestimation of the LVSV and hence, to an overesti-
mation of MR severity in MVP patients. Similarly, in
patients with MVP but without MR, the corrected LVSV
should be in agreement with the reference stroke
volume of the RV (i.e. it should avoid a LVSV vs
RVSV difference) or aortic forward flow volume. The
amount of error of standard, uncorrected LVESV mea-
surements is expected to be proportional to the height of
the valve prolapse, i.e. to the “prolapsed volume”.
Accordingly, in this study, we proposed a simple
strategy to correct the LVESV for the severity of the pro-
lapse, i.e. for the “prolapsed volume”, and we assessed its




A retrospective search was conducted in our CMR
centre between January 2011 and January 2017 to iden-
tify the patients, for which the presence of bileaflet MVP
could be suspected. The keywords “prolapse”,
“billowing”, “Barlow”, and “Marfan” were used to screen
the CMR reports and 105 patients were identified. The
images were individually reviewed to only include
patients presenting with bileaflet MVP, defined as the
billowing of both, the anterior and posterior mitral leaf-
lets, with displacement of the leaflets >2 mm into the
LA on a 3 chamber long-axis view in systole [4]. The
clinical records were analyzed for the presence of aortic,
mitral, tricuspid or pulmonary regurgitation detected by
any other means (usually echocardiography). Patients
were excluded if they had more than mild regurgitation
of the aortic or pulmonary valve, more than trace regur-
gitation of the tricuspid valve, or any intracardiac shunt.
CMR acquisition
Image acquisition was performed on a 1.5 T (Magnetom
AERA or Magnetom Symphony) or a 3.0 T (Magnetom
Verio or Magnetom Skyra) scanner (Siemens Healthcare,
Erlangen Germany) using a 32-channels phased-array
coil. A balanced steady-state free precession cine
sequence was used for ventricular volume assessment
(typical parameters TR 3.06 ms, TE 1.28 ms, flip angle
60°, FOV 300 × 240 mm, voxel size 1.2 × 1.2 × 8.0 mm,
16 lines/segment, 25 phases/cardiac cycle). A stack of
short axis slices (slice thickness 8 mm and 2 mm gap)
from the base to the apex, as well as 3 long-axis slices of
the LV, were acquired in all patients. When clinically in-
dicated, a phase-contrast acquisition of the ascending
aorta was additionally performed during breath-hold
(typical parameters TR 10.5 ms, TE 3.04 ms, flip angle
20°, FOV 340 × 238 mm, voxel size 1.8 × 1.8 × 6.0 mm,
4 lines/segment, 20 phases/cardiac cycle, VENC 150 cm/s);
the imaging plane for aortic forward flow measurement
was defined from two orthogonal long axis cine acquisi-
tions of the ascending aorta and was placed at the level of
the right pulmonary artery.
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Image analysis
The ventricular volumes were measured according to
the Simpson’s method of disks by tracing the endocardial
LV border from the basal to the apical slice using a
semi-automated border detection software (GTvolume®,
Gyrotools, Zürich, Switzerland). Muscular trabeculae
were included in the blood pool. For end-diastolic
(LVEDV) and uncorrected end-systolic (LVESVuncorr) LV
volumes, the basal slice was defined as the slice with LV
myocardium detected at least 50% of its circumference
[19, 20]. In case of uncertainty, cross-referencing of
basal short axis and long axis views was used. A
prolapse-corrected LV end-systolic volume (LVESVcorr)
was additionally measured as the standard LVESV
(=LVESVuncorr) plus the prolapsed volume. The prolapsed
volume was calculated as the area of the basal end-sys-
tolic slice multiplied by the mean prolapsed height. The
mean prolapsed height was the average of the three in-
dividual prolapsed heights of the three standard LV
long-axis views of the LV (ie 2-, 3-, and 4-chamber
views), calculated as the prolapsed area divided by the
annulus diameter (Fig. 1). This strategy aimed to obtain
a better coverage of the mitral valve and its 6 different
scallops (Fig. 2) to more accurately estimate the prolapsed
volume as patients not infrequently present with asym-
metrical prolapses or prolapses predominantly involving
the posterior mitral leaflet. The uncorrected LV stroke
volume (LVSVuncorr) was calculated as the LVEDV
minus the LVESVuncorr. The prolapse-corrected stroke
volume (LVSVcorr) was calculated as the LVEDV minus
LVESVcorr.
The RV volumes were measured from the same set of
short-axis cine images in all patients according to the
Simpson’s method of disks by tracing the endocardial
RV border from the basal to the apical slice using the
same semi-automated border detection software. Cross-
referencing with a long axis four-chamber cine acquisi-
tion was performed in all patients to accurately identify
the basal RV slice. The RVSV was calculated as the
difference between the end-diastolic and end-systolic RV
Fig. 1 Severe bileaflet mitral valve prolapse in a patient with Marfan syndrome. Top row: diastolic frames in 4-, 2- and 3-chamber orientations.
Mid row: corresponding systolic frames. Bottom row: on each systolic view, the prolapsed area is measured by planimetry (green area). This area is
divided by the mitral annular diameter (red line) to calculate the prolapsed height. The average of the three calculated prolapsed heights gives
the mean prolapsed height of the mitral valve
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volume and was considered the reference stroke volume
in view of the fact that tricuspid insufficiency was a
study exclusion criteria. When available, the aortic
forward flow (Aoforward) corrected for background phase
was measured on phase-contrast cine images of the
ascending aorta by manually tracing the aortic surface
frame-by-frame using the Argus workstation (Siemens
Healthcare, Erlangen, Germany).
For the assessment of MR severity, the regurgitant
volume was calculated as the difference between the
LVSVuncorr and the RVSV (= standard or uncorrected
method) and between the LVSVcorr and the RVSV (=
corrected method). For both methods, the RF was
calculated as the ratio between the respective regurgitant
volume and the respective LVSV. A RF <5% defined
absent or trace MR, 5–29% mild MR, 30–49% moderate
MR, and ≥50% severe MR [21].
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation and categorical variables as percentages. The
correlations and agreements between uncorrected and
corrected LVSV were analyzed by linear regression and
Bland-Altman statistics [22]. Direct comparisons of
baseline characteristics were performed with paired
t-tests. Direct comparison between LVSV and the refer-
ence stroke volume were performed with Wilcoxon
matched-pairs signed ranks test. The comparison of the
MR grade distribution was performed with Chi-square
test. All calculations were performed with Stata 14
software (StataCorp LP, Texas, USA). A p-value <0.05
was considered as significant.
Results
Patient population
Forty-two patients were identified with bileaflet MVP.
One patient was excluded due to the presence of an
atrial septal defect with significant left-to-right shunt
and six patient had mild or moderate tricuspid regurgi-
tation. Thirty-five patients were therefore included in
the analysis. Mean age was 44.0 ± 23.0 years and 14
(40%) were male. Fifteen patients (42.9%) with MVP had
no or only trace MR detected on echocardiography, or
no MR jet detected on the 3 long axis or basal short-axis
cine CMR acquisitions. Additional baseline characteris-
tics are summarized in Table 1.
Reference stroke volume
RVSV was measured in all patients with a mean value of
71.5 ± 24.9 ml. AOforward measured by phase-contrast
cine CMR was available in 24 patients (68.6%) and was
highly correlated with RVSV (R2 = 0.97, p < 0.001).
Agreement between the two methods was also excellent
(difference: −0.1 ml; 95%-confidence interval −8.7 to
8.5 ml, p = 0.92 vs 0). All analyses were performed using
RVSV (n = 35) as the reference stroke volume. The same
analyses were repeated in the subset of patients (n = 24)
with AOforward as the reference stroke volume, and the
corresponding results were indicated for comparison.
Reproducibility of prolapsed volume measurement
Intra-observer analysis of prolapsed volume measure-
ment (n = 35) indicated a good agreement: mean
difference: −0.4 ml (95%-confidence interval: −3.6 to
2.8 ml). The inter-observer analysis indicated a mean
difference of −2.6 ml (95%-confidence interval: −8.8 to
3.6 ml). In the subgroup of patients assessed with a 1.5 T
scanner (n = 26), the mean differences were 0.1 ml (95%-
confidence interval: −2.3 to 2.5 ml) and −2.3 ml (−8.7 to
4.1 ml) for intra- and inter-observer analysis, respectively.
In the subgroup of patients assessed with a 3.0 T scanner
(n = 9), the mean differences were −1.8 ml (95%-confi-
dence interval: −5.5 to 2.0 ml) and −3.6 ml (−9.2 to
2.0 ml) for intra- and inter-observer analysis, respectively.
Agreement between reference RVSV and LVSV in patients
with no MR
Fifteen patients (42.9%) had no or only trace MR and
their reference RVSV was 83.6 ± 28.6 ml. The mean
prolapsed height was 7.6 ± 2.1 mm and the prolapsed vol-
ume was 14.4 ± 7.0 ml. The LVSVcorr was significantly
lower than the LVSVuncorr (86.1 ± 31.6 ml vs 100.6 ±
35.8 ml, p < 0.0001). In the patients with no MR, the
LVSVuncorr exceeded the true reference RVSV by 16.9 ±
Fig. 2 Morphology of the mitral valve according to the Carpentier’s
classification. The posterior mitral leaflet is naturally separated by
cleft like indentations into 3 scallops (P1, P2 and P3). The corresponding
segments of the anterior leaflet are called A1, A2 and A3. The long axis
3-chamber view will cut the A2 and P2 scallops of the mitral valve, the
2-chamber view the A1, A2 and P3 scallops, and the 4-chamber view the
P1, A2 and A3 scallops
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9.1 ml (p = 0.0007 vs 0), while a non-significant 2.5 ±
4.7 ml overestimation was observed with the LVSVcorr (p
= 0.11 vs 0; Fig. 3). In 8 of these patients, AOforward was
available as reference stroke volume and a similar over-
estimation of AOforward was found with LVSVuncorr (mean
difference 18.3 ± 11.8 ml, p = 0.01 vs 0) but not with
LVSVcorr (mean difference 4.8 ± 6.6 ml, p = 0.16 vs 0).
Impact of prolapse severity on MR severity grading
Over the whole cohort (n = 35), the prolapsed height
correlated linearly with the difference between uncorrected,
and the corrected stroke volume (r2 = 0.66, p < 0.0001). The
uncorrected and corrected method provided significantly
different results for LVSV (102.2 ± 32.3 vs 85.7 ± 30.2 ml,
respectively, p < 0.0001), LVEF (66.4 ± 7.3 vs 55.6 ± 8.3%,
respectively, p < 0.0001), regurgitant volume (30.7 ± 20.2 vs
14.1 ± 18.8 ml, respectively, p < 0.0001) and regurgitant
fraction (29.0 ± 14.7 vs 14.9 ± 16.3%, respectively, p <
0.0001) (Fig. 4). Accordingly, the distribution of the patients
among the four classes of MR severity (none or trace/mild/
moderate/severe) was significantly different for the uncor-
rected and the corrected methods (0/20/11/4 vs 11/18/5/1,
respectively, p < 0.001). Overall, the grade of MR severity
was concordant for the two methods in only 12 patients
(34%), as the uncorrected method overestimated MR
severity by 1 grade in 23 (66%) patients (Fig. 5). In the
subgroup of patients known for having no MR (n = 15),
CMR suggested the presence of a mild MR in all patients
when the uncorrected method was used (with a mean
regurgitant volume of 16.9 ± 9.1 ml and a mean regurgi-
tant fraction of 16.3 ± 5.9%). With the corrected method,
11 out of the 15 patients were correctly classified as
having no significant MR. In 4 patients, MR grade was still
overestimated by one grade despite low regurgitant
volumes (mean regurgitant volume of 7.9 ± 2.6 ml, mean
regurgitant fraction of 8.2 ± 3.4%).
Among the subset of patients where AOforward was
available (n = 24), the uncorrected method resulted in a
similar overestimation of the LVSV (104.8 ± 33.1 vs
88.0 ± 31.1 ml, p < 0.0001), the LVEF (66.4 ± 7.9 vs
55.8 ± 8.7%, p < 0.0001), the regurgitant volume (35.1 ± 22.4
vs 18.4 ± 20.9 ml, p < 0.0001) and the regurgitant fraction
(32.2 ± 16.2 vs 19.3 ± 17.6%, p < 0.0001). MR grade severity
was concordant between the corrected and the uncorrected
methods in only 10 (41.7%) patients, and an overestimation
by one grade was observed in 14 (58.3%) patients.
Discussion
In the MVP population, the present study suggests a
correction of the LVSV by the prolapsed volume, i.e. by
Table 1 Patients characteristics
All patients (n = 35) No MR (n = 15) Significant MR (n = 20) p
Age (years) 44.0 ± 23.0 38.1 ± 19.1 48.5 ± 25.1 0.19
Height (cm) 174.5 ± 12.4 178.1 ± 13.2 171.9 ± 11.4 0.14
Weight (kg) 62.4 ± 15.9 64.5 ± 18.8 60.8 ± 13.7 0.5
BMI (kg/m2) 20.3 ± 3.8 20.1 ± 4.3 20.4 ± 3.4 0.82
LVEDV (ml) 155.4 ± 51.1 151.5 ± 58.3 158.4 ± 46.3 0.7
LVEDV index (ml/m2) 88.5 ± 22.8 83.4 ± 22.6 92.2 ± 22.8 0.27
LVESV uncorrected (ml) 53.3 ± 23.3 50.9 ± 25.6 55.0 ± 22.0 0.62
LVESV corrected (ml) 69.8 ± 28.4 65.3 ± 29.7 73.1 ± 27.8 0.43
LVEF standard (%) 66.4 ± 7.3 67.2 ± 7.1 65.7 ± 7.6 0.56
LVEF corrected (%) 55.6 ± 8.3 57.6 ± 7.2 54.1 ± 8.9 0.22
Prolapsed height (mm) 8.1 ± 2.8 7.6 ± 2.1 8.5 ± 3.2 0.32
Prolapsed volume (ml) 16.5 ± 8.7 14.4 ± 7.0 18.1 ± 9.6 0.22
RVEDV (ml) 140.1 ± 46.3 157.4 ± 55.6 127.2 ± 33.8 0.05
RVESV (ml) 68.6 ± 24.5 73.8 ± 28.7 64.7 ± 20.9 0.29
RVEF (%) 51.0 ± 6.6 53.5 ± 5.3 49.1 ± 7.0 0.05
Indication for CMR (n; %)
• Marfan syndrome 11 (31) 6 (40) 5 (25) 0.02
• MR quantification 9 (26) 0 (0) 9 (45)
• Ventricular arrhythmia 7 (20) 6 (40) 1 (5)
• Ischemia detection 5 (14) 2 (13) 3 (15)
• Suspicion of myocarditis 1 (3) 0 (0) 1 (5)
• Malformation syndromes 2 (6) 1 (7) 1 (5)
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the volume “contained” within the prolapsing mitral
valve leaflets, impacts on the quantification of MR. This
correction reduced the MR severity by one grade in 66%
of patients. In the case of a prominent MVP, the mitral
annulus is not an adequate landmark to separate the LV
from the LA volume in systole, as the systolic billowing
of the mitral valve into the LA creates a space in the LA
that is occupied by the LV blood pool. This part of the
LV blood pool (i.e. the prolapsed volume) is not crossing
through the incompetent mitral valve in systole. i.e. this
volume does not contribute to the regurgitant volume of
the prolapsing mitral valve, and should therefore be cor-
rected for. Accordingly, in the situation of MVP, the
proximal border of the LV blood pool is the plane of the
mitral valve leaflets, not the mitral annulus. As the mi-
tral valve is a thin structure, it is difficult to recognize
on short-axis cine slices of the LV and we propose a
method using the 3 long-axis orientations to correct the
standard LVESV for the prolapsed volume. In the pa-
tients known for having no or only trace MR, a better
agreement was found between the LVSVcorr and the ref-
erence RVSV with this correction for the prolapsed vol-
ume. Over the whole cohort of patients with MVP, this
correction resulted in a difference in MR severity quanti-
fication by 1 grade in almost two thirds of the patients.
In addition, with this correction, LV ejection fraction
was also significantly lower, reflecting the ineffective
pump function caused by the systolic displacement of
the mitral valve plane into the LA.
With regard to the need to undergo MV surgery, one
single recent study proposed a validated cut-off value for
RegVol and RF with CMR [10], and no general consensus
exists regarding the most appropriate CMR quantifica-
tion technique. Several CMR approaches have been used
including the comparison of the LVSV with the RVSV
[13], LVSV with the Aoforward by phase-contrast cine im-
aging [15, 17], trans-mitral forward flow with Aoforward
[12, 23], or by direct measurement of the regurgitant
orifice area [24]. However, these methods were not spe-
cifically validated for MVP patients and they seem not to
Fig. 3 Comparison of LVSV and reference SV in 15 patients with no significant mitral regurgitation. Regression (top panels) and Bland-Altman (bottom
panels) plots comparing LVSV and the reference stroke volume (RVSV) in 15 patients with no significant mitral regurgitation. With the uncorrected
method, the LVSV was higher than the reference stroke volume (left hand panels), while with the corrected method, no significant difference was
measured (right hand panels). a Correlation between uncorrected and reference SV in patients with no mitral regurgitation b Correlation between
corrected and reference SV in patients with no mitral regurgitation (MR) c Agreement between uncorrected and reference SV in patients with no MR
d Agreement between corrected and reference SV in patients with no MR
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be interchangeable, as they can differ in quantitative
measures of regurgitation as well as with respect to
inter-observer reproducibilities [25, 26]. In case of MVP,
the present study suggests that MR quantification has to
be adapted to the mechanism of MR to minimize the
risk of misclassification. Our population essentially
consisted of patients with severe MVP and the mean
prolapsed volume was as large as 16 ml, indicating, the-
oretically, that the calculated regurgitant volume was
systematically overestimated by 16 ml. This volume is by
no means negligible as it represents one fourth of the
cut-off value, which defines a severe MR [21]. Not sur-
prisingly, this systematic error resulted in an overesti-
mation of MR severity by one grade in almost two thirds
of the MVP patients.
From a clinical perspective, mitral valve surgery is in-
dicated in patients with severe MR, who present with
symptoms or evidence of LV dilatation or dysfunction
Fig. 4 Impact of end-systolic volume correction on the LV function and MR severity assessment. The left ventricular stroke volume (LVSV, panel
a), LV ejection fraction (LVEF, panel b), regurgitant volume across the mitral valve (panel c) and mitral regurgitant fraction (panel d) all appear
significantly higher when measured with the uncorrected method
Fig. 5 Impact of end-systolic volume correction on MR severity grading. The uncorrected method indicated a 1 grade higher MR severity than
the corrected method in 66% of the patients
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[27], but there is evidence suggesting that early surgery
of severe MR before the onset of symptoms or LV
dysfunction might be beneficial in terms of long term
prognosis if the morphology of the valve allows a suc-
cessful durable repair [28]. Mitral valve repair is more
challenging in the presence of severe bileaflet MVP due
to the diffuse nature of the morphologic changes and
valve replacement may be the only surgical option for
some patients [6, 29]. Accordingly, a correct quantifica-
tion of MR is crucial to avoid unnecessary operations.
The consequences of early surgery in patients with non--
severe MR could include a higher risk of re-do surgery
later in life and it would increase morbidity in the pa-
tients for whom mitral valve repair was not possible
resulting in mitral valve replacement. The appropriate
timing of the first surgical repair is of particular import-
ance for patients with MVP as they typically represent a
relatively young population, where the perspective of re-
do surgery exists despite excellent long-term results of
surgical mitral valve repair [30]. Finally, a systematic
overestimation of MR severity may generate additional
unnecessary follow-up visits and create anxiety to the
patient. As an illustration, by using the cut-off values
prospectively validated by Myerson et al. (RegVol
>55 ml or a RF >40%) [10], and applying the standard
uncorrected method, 9 (26%) patients would be consid-
ered as potential candidates for surgery versus only 4
(11%, p = 0.002) when using the proposed correction
method, which considers the prolapsed volume, i.e. the
severity of the valve prolapse.
The limitations of this study include the relatively small
number of participating patients and the specific mechan-
ism of valve disease investigated, which is not representa-
tive for other types of MR. The retrospective design of this
study may have selected patients with a more severe de-
gree of MVP (mean prolapsed height was 8.1 mm) and
the risk of MR misclassification may be less important for
patients with milder degrees of MVP. We are therefore
not able to recommend a cut-off value of prolapsed height
above which a LVSV correction might be warranted. In
this study, the prolapsed volume has been estimated and
not directly measured. The geometric assumptions associ-
ated with our correction strategy might have induced
some variability in the measurements. However, the
proposed correction method can be easily applied to con-
ventional CMR protocols which typically include a LV
short-axis stack and 3 long-axis cine acquisitions. In this
regard, the development of a time-efficient truly three-
dimensional technique to accurately measure the prolapsed
volume might be of value. Finally no direct comparison
with echocardiographic MR quantification was performed
in this cohort, as the aim of this study was not to compare
the performance of two different imaging methods, but to
highlight a potential methodological bias induced by MVP
when the quantification of MR severity is performed with a
generally accepted standard CMR method.
Conclusion
When applying the standard method of discs to measure
LV volumes in patients with MVP, the blood volume
contained within the valve prolapse is not considered to
be part of the LV volume in systole. Consequently, in a
severe form of bileaflet prolapse, this may lead to a sig-
nificant underestimation of the true end-systolic volume
and thus, overestimation of MR severity. For these pa-
tients, we suggest to correct the LVSV for the pro-
lapsed volume, as it allowed a reclassification of MR
severity to a milder grade in two thirds of the MVP
patients.
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